RU2335295C2 - Способы получения композиций, включающих хитшоковые белки или альфа-2-макроглобулин, пригодных для лечения злокачественной опухоли и инфекционного заболевания - Google Patents

Info

Publication number

RU2335295C2

RU2335295C2 RU2004108129/15A RU2004108129A RU2335295C2 RU 2335295 C2 RU2335295 C2 RU 2335295C2 RU 2004108129/15 A RU2004108129/15 A RU 2004108129/15A RU 2004108129 A RU2004108129 A RU 2004108129A RU 2335295 C2 RU2335295 C2 RU 2335295C2

Authority

RU

Russia

Prior art keywords

cells

antigenic

proteins

peptides

hitshock

Prior art date

2001-08-20

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 232
• 201000011510 cancer Diseases 0.000 title claims abstract description 97
• 239000000203 mixture Substances 0.000 title claims abstract description 71
• 238000011282 treatment Methods 0.000 title claims abstract description 49
• 208000035473 Communicable disease Diseases 0.000 title claims abstract description 47
• 208000015181 infectious disease Diseases 0.000 title claims abstract description 43
• 108010004889 Heat-Shock Proteins Proteins 0.000 title abstract description 13
• 102000002812 Heat-Shock Proteins Human genes 0.000 title abstract description 13
• 102100033312 Alpha-2-macroglobulin Human genes 0.000 title description 217
• 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 title description 14
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 381
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 360
• 230000000890 antigenic effect Effects 0.000 claims abstract description 332
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 299
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 249
• 238000002360 preparation method Methods 0.000 claims abstract description 108
• 102000035195 Peptidases Human genes 0.000 claims abstract description 50
• 108091005804 Peptidases Proteins 0.000 claims abstract description 50
• 235000019833 protease Nutrition 0.000 claims abstract description 44
• 238000000338 in vitro Methods 0.000 claims abstract description 40
• 230000002265 prevention Effects 0.000 claims abstract description 23
• 230000028993 immune response Effects 0.000 claims abstract description 22
• 230000001413 cellular effect Effects 0.000 claims abstract description 12
• 230000002163 immunogen Effects 0.000 claims abstract description 9
• 238000006911 enzymatic reaction Methods 0.000 claims abstract description 7
• 210000004027 cell Anatomy 0.000 claims description 434
• 206010028980 Neoplasm Diseases 0.000 claims description 86
• 239000000427 antigen Substances 0.000 claims description 68
• 108091007433 antigens Proteins 0.000 claims description 66
• 102000036639 antigens Human genes 0.000 claims description 65
• 239000012528 membrane Substances 0.000 claims description 40
• 238000003776 cleavage reaction Methods 0.000 claims description 35
• 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 33
• 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 33
• 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 33
• 230000007017 scission Effects 0.000 claims description 33
• 230000001086 cytosolic effect Effects 0.000 claims description 30
• 239000012678 infectious agent Substances 0.000 claims description 20
• 101710113864 Heat shock protein 90 Proteins 0.000 claims description 19
• 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 19
• -1 gp96 Proteins 0.000 claims description 15
• 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 14
• 108020003519 protein disulfide isomerase Proteins 0.000 claims description 14
• 125000000539 amino acid group Chemical group 0.000 claims description 13
• 230000015572 biosynthetic process Effects 0.000 claims description 12
• 108010058432 Chaperonin 60 Proteins 0.000 claims description 11
• 210000005260 human cell Anatomy 0.000 claims description 11
• 239000003795 chemical substances by application Substances 0.000 claims description 10
• 108020004707 nucleic acids Proteins 0.000 claims description 10
• 102000039446 nucleic acids Human genes 0.000 claims description 10
• 150000007523 nucleic acids Chemical class 0.000 claims description 10
• 238000010668 complexation reaction Methods 0.000 claims description 9
• 108090000549 Calreticulin Proteins 0.000 claims description 8
• 230000001939 inductive effect Effects 0.000 claims description 7
• 108090000631 Trypsin Proteins 0.000 claims description 6
• 102000004142 Trypsin Human genes 0.000 claims description 6
• 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 6
• 108010008714 glucose-regulated protein 170 Proteins 0.000 claims description 6
• 239000012588 trypsin Substances 0.000 claims description 6
• 108090000317 Chymotrypsin Proteins 0.000 claims description 4
• 239000002671 adjuvant Substances 0.000 claims description 4
• 229960002376 chymotrypsin Drugs 0.000 claims description 4
• 239000003431 cross linking reagent Substances 0.000 claims description 4
• 210000003463 organelle Anatomy 0.000 claims description 4
• 238000000926 separation method Methods 0.000 claims description 4
• LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 claims description 3
• 108090000617 Cathepsin G Proteins 0.000 claims description 3
• 102000004173 Cathepsin G Human genes 0.000 claims description 3
• 108010067372 Pancreatic elastase Proteins 0.000 claims description 3
• 102000016387 Pancreatic elastase Human genes 0.000 claims description 3
• 108090000526 Papain Proteins 0.000 claims description 3
• 102000057297 Pepsin A Human genes 0.000 claims description 3
• 108090000284 Pepsin A Proteins 0.000 claims description 3
• 239000004365 Protease Substances 0.000 claims description 3
• 108090001109 Thermolysin Proteins 0.000 claims description 3
• 229940055729 papain Drugs 0.000 claims description 3
• 235000019834 papain Nutrition 0.000 claims description 3
• 229940111202 pepsin Drugs 0.000 claims description 3
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
• 230000002132 lysosomal effect Effects 0.000 claims description 2
• 230000002438 mitochondrial effect Effects 0.000 claims description 2
• 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims 6
• 102000004082 Calreticulin Human genes 0.000 claims 5
• 101150051208 HSPH1 gene Proteins 0.000 claims 5
• 102100031624 Heat shock protein 105 kDa Human genes 0.000 claims 5
• 101100071630 Mesocentrotus franciscanus HSP110 gene Proteins 0.000 claims 5
• 101100451677 Mus musculus Hspa4 gene Proteins 0.000 claims 5
• 230000002779 inactivation Effects 0.000 claims 1
• 230000000694 effects Effects 0.000 abstract description 13
• 239000003814 drug Substances 0.000 abstract description 5
• 239000000126 substance Substances 0.000 abstract description 3
• 230000006806 disease prevention Effects 0.000 abstract 1
• 238000012423 maintenance Methods 0.000 abstract 1
• 230000003449 preventive effect Effects 0.000 abstract 1
• 235000018102 proteins Nutrition 0.000 description 307
• 101710187168 Alpha-2-macroglobulin Proteins 0.000 description 211
• 101710136034 Alpha-2-macroglobulin homolog Proteins 0.000 description 211
• 244000052769 pathogen Species 0.000 description 38
• 210000004379 membrane Anatomy 0.000 description 37
• 239000002245 particle Substances 0.000 description 36
• 239000006228 supernatant Substances 0.000 description 35
• 230000003612 virological effect Effects 0.000 description 35
• 230000003211 malignant effect Effects 0.000 description 34
• 230000001717 pathogenic effect Effects 0.000 description 32
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 31
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 30
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 30
• 108020004414 DNA Proteins 0.000 description 29
• 230000002255 enzymatic effect Effects 0.000 description 28
• 229920001184 polypeptide Polymers 0.000 description 24
• 241000700605 Viruses Species 0.000 description 23
• 239000000872 buffer Substances 0.000 description 22
• 238000004519 manufacturing process Methods 0.000 description 22
• 210000004881 tumor cell Anatomy 0.000 description 22
• 210000000612 antigen-presenting cell Anatomy 0.000 description 21
• 238000005119 centrifugation Methods 0.000 description 21
• 230000014509 gene expression Effects 0.000 description 20
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
• 230000027455 binding Effects 0.000 description 19
• 210000001519 tissue Anatomy 0.000 description 19
• 241000699670 Mus sp. Species 0.000 description 18
• 210000001744 T-lymphocyte Anatomy 0.000 description 18
• 238000009169 immunotherapy Methods 0.000 description 18
• 238000002955 isolation Methods 0.000 description 18
• 239000013598 vector Substances 0.000 description 17
• 239000000463 material Substances 0.000 description 16
• 239000011780 sodium chloride Substances 0.000 description 16
• 239000007924 injection Substances 0.000 description 15
• 238000002347 injection Methods 0.000 description 15
• 238000004458 analytical method Methods 0.000 description 14
• 239000012634 fragment Substances 0.000 description 14
• 108010062580 Concanavalin A Proteins 0.000 description 13
• 230000000536 complexating effect Effects 0.000 description 13
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
• 239000013604 expression vector Substances 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 239000011575 calcium Substances 0.000 description 12
• 230000002378 acidificating effect Effects 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• 210000000172 cytosol Anatomy 0.000 description 11
• 201000010099 disease Diseases 0.000 description 11
• 238000005755 formation reaction Methods 0.000 description 11
• 230000003053 immunization Effects 0.000 description 11
• 238000002649 immunization Methods 0.000 description 11
• 239000011777 magnesium Substances 0.000 description 11
• 238000011321 prophylaxis Methods 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 102000004127 Cytokines Human genes 0.000 description 10
• 108090000695 Cytokines Proteins 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 10
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 10
• 235000011130 ammonium sulphate Nutrition 0.000 description 10
• 230000006862 enzymatic digestion Effects 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 230000003834 intracellular effect Effects 0.000 description 10
• 239000012139 lysis buffer Substances 0.000 description 10
• 210000004962 mammalian cell Anatomy 0.000 description 10
• 238000003752 polymerase chain reaction Methods 0.000 description 10
• 239000002244 precipitate Substances 0.000 description 10
• 230000000069 prophylactic effect Effects 0.000 description 10
• 239000000523 sample Substances 0.000 description 10
• 239000012064 sodium phosphate buffer Substances 0.000 description 10
• 241000894006 Bacteria Species 0.000 description 9
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
• 108060003951 Immunoglobulin Proteins 0.000 description 9
• 229920002684 Sepharose Polymers 0.000 description 9
• 235000001014 amino acid Nutrition 0.000 description 9
• 150000001413 amino acids Chemical group 0.000 description 9
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
• 102000018358 immunoglobulin Human genes 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 239000006166 lysate Substances 0.000 description 9
• 239000002773 nucleotide Substances 0.000 description 9
• 125000003729 nucleotide group Chemical group 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 241000282412 Homo Species 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 108010076504 Protein Sorting Signals Proteins 0.000 description 8
• 210000004443 dendritic cell Anatomy 0.000 description 8
• 230000036039 immunity Effects 0.000 description 8
• 239000011541 reaction mixture Substances 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 7
• 238000000227 grinding Methods 0.000 description 7
• 210000000987 immune system Anatomy 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 210000002540 macrophage Anatomy 0.000 description 7
• 239000008363 phosphate buffer Substances 0.000 description 7
• 239000002504 physiological saline solution Substances 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 239000002299 complementary DNA Substances 0.000 description 6
• 238000002591 computed tomography Methods 0.000 description 6
• 238000001914 filtration Methods 0.000 description 6
• 210000002865 immune cell Anatomy 0.000 description 6
• 230000005847 immunogenicity Effects 0.000 description 6
• 244000045947 parasite Species 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 238000009210 therapy by ultrasound Methods 0.000 description 6
• 241000701161 unidentified adenovirus Species 0.000 description 6
• 241000283690 Bos taurus Species 0.000 description 5
• 102000006303 Chaperonin 60 Human genes 0.000 description 5
• 206010009944 Colon cancer Diseases 0.000 description 5
• 241000701022 Cytomegalovirus Species 0.000 description 5
• 241000233866 Fungi Species 0.000 description 5
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 5
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 5
• 230000003044 adaptive effect Effects 0.000 description 5
• 125000003275 alpha amino acid group Chemical group 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 238000004140 cleaning Methods 0.000 description 5
• 238000010367 cloning Methods 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 102000037865 fusion proteins Human genes 0.000 description 5
• 108020001507 fusion proteins Proteins 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 210000004408 hybridoma Anatomy 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 210000004940 nucleus Anatomy 0.000 description 5
• 239000008188 pellet Substances 0.000 description 5
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 5
• 238000003259 recombinant expression Methods 0.000 description 5
• 230000035939 shock Effects 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
• 208000009889 Herpes Simplex Diseases 0.000 description 4
• 102100037850 Interferon gamma Human genes 0.000 description 4
• 108010074328 Interferon-gamma Proteins 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 102000043129 MHC class I family Human genes 0.000 description 4
• 108091054437 MHC class I family Proteins 0.000 description 4
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
• 241001631646 Papillomaviridae Species 0.000 description 4
• 241000606701 Rickettsia Species 0.000 description 4
• 206010039491 Sarcoma Diseases 0.000 description 4
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
• 230000005867 T cell response Effects 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 238000001574 biopsy Methods 0.000 description 4
• 238000010382 chemical cross-linking Methods 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 208000032839 leukemia Diseases 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 230000002797 proteolythic effect Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 230000002269 spontaneous effect Effects 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 102100029968 Calreticulin Human genes 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
• 102000006992 Interferon-alpha Human genes 0.000 description 3
• 108010047761 Interferon-alpha Proteins 0.000 description 3
• 102000000588 Interleukin-2 Human genes 0.000 description 3
• 108090000978 Interleukin-4 Proteins 0.000 description 3
• 102000004388 Interleukin-4 Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• 102000004889 Interleukin-6 Human genes 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 239000012979 RPMI medium Substances 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 239000000090 biomarker Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 210000002421 cell wall Anatomy 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 230000009918 complex formation Effects 0.000 description 3
• 230000001461 cytolytic effect Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 239000003599 detergent Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 238000003119 immunoblot Methods 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 239000002198 insoluble material Substances 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 230000001613 neoplastic effect Effects 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 230000000269 nucleophilic effect Effects 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 230000001855 preneoplastic effect Effects 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000011285 therapeutic regimen Methods 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• OUSKVHOYPHDTIA-DBRKOABJSA-N (3s,4s,5r,6r)-3,4,5,6,7-pentahydroxyheptan-2-one Chemical compound CC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OUSKVHOYPHDTIA-DBRKOABJSA-N 0.000 description 2
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 2
• VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 2
• 101100124795 Caenorhabditis elegans hsp-110 gene Proteins 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 241000224483 Coccidia Species 0.000 description 2
• 241000709687 Coxsackievirus Species 0.000 description 2
• 229920002271 DEAE-Sepharose Polymers 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 241001466953 Echovirus Species 0.000 description 2
• 241000709661 Enterovirus Species 0.000 description 2
• 241000991587 Enterovirus C Species 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 108050001049 Extracellular proteins Proteins 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 101150076784 HSP100 gene Proteins 0.000 description 2
• 101150031823 HSP70 gene Proteins 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 2
• ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000589248 Legionella Species 0.000 description 2
• 208000007764 Legionnaires' Disease Diseases 0.000 description 2
• 241000222722 Leishmania <genus> Species 0.000 description 2
• 108091054438 MHC class II family Proteins 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 208000002720 Malnutrition Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 108090000157 Metallothionein Proteins 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241000711386 Mumps virus Species 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 102000008300 Mutant Proteins Human genes 0.000 description 2
• 108010021466 Mutant Proteins Proteins 0.000 description 2
• 241000204031 Mycoplasma Species 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• 206010035148 Plague Diseases 0.000 description 2
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
• 102100038358 Prostate-specific antigen Human genes 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 241000725643 Respiratory syncytial virus Species 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 241000702670 Rotavirus Species 0.000 description 2
• 241000710799 Rubella virus Species 0.000 description 2
• 239000012506 Sephacryl® Substances 0.000 description 2
• 229920005654 Sephadex Polymers 0.000 description 2
• 239000012507 Sephadex™ Substances 0.000 description 2
• 102000012479 Serine Proteases Human genes 0.000 description 2
• 108010022999 Serine Proteases Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 241000607479 Yersinia pestis Species 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 239000007801 affinity label Substances 0.000 description 2
• 230000007503 antigenic stimulation Effects 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000007969 cellular immunity Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 150000001875 compounds Chemical class 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 229960003964 deoxycholic acid Drugs 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
• 235000019441 ethanol Nutrition 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 238000005194 fractionation Methods 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 239000000185 hemagglutinin Substances 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 239000000367 immunologic factor Substances 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 230000001071 malnutrition Effects 0.000 description 2
• 235000000824 malnutrition Nutrition 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000005087 mononuclear cell Anatomy 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000005170 neoplastic cell Anatomy 0.000 description 2
• 230000009826 neoplastic cell growth Effects 0.000 description 2
• 208000015380 nutritional deficiency disease Diseases 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 238000000164 protein isolation Methods 0.000 description 2
• RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000031070 response to heat Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000013605 shuttle vector Substances 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 239000007974 sodium acetate buffer Substances 0.000 description 2
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 229950009811 ubenimex Drugs 0.000 description 2
• 241000712461 unidentified influenza virus Species 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
• KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 101150094949 APRT gene Proteins 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• 108010068307 Alpha-Globulins Proteins 0.000 description 1
• 102000002572 Alpha-Globulins Human genes 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 108010087765 Antipain Proteins 0.000 description 1
• 102000006410 Apoproteins Human genes 0.000 description 1
• 108010083590 Apoproteins Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 108020004256 Beta-lactamase Proteins 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
• 108010059892 Cellulase Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 101800004419 Cleaved form Proteins 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 102000015833 Cystatin Human genes 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 1
• 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
• 238000011510 Elispot assay Methods 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 101710122227 Epstein-Barr nuclear antigen 1 Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 101000738180 Euglena gracilis Chaperonin CPN60, mitochondrial Proteins 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000799972 Homo sapiens Alpha-2-macroglobulin Proteins 0.000 description 1
• 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
• 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 description 1
• 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 1
• 101001036709 Homo sapiens Heat shock protein beta-1 Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 108010093096 Immobilized Enzymes Proteins 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 description 1
• 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 235000019687 Lamb Nutrition 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
• 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 1
• 206010024305 Leukaemia monocytic Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 108010010995 MART-1 Antigen Proteins 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
• 241000712079 Measles morbillivirus Species 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 206010054949 Metaplasia Diseases 0.000 description 1
• PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
• 102000015728 Mucins Human genes 0.000 description 1
• 108010063954 Mucins Proteins 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 101000899228 Mus musculus Endoplasmic reticulum chaperone BiP Proteins 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 241000588653 Neisseria Species 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
• 108700006385 OmpF Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241000150452 Orthohantavirus Species 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 240000006711 Pistacia vera Species 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 241001068295 Replication defective viruses Species 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 101800001271 Surface protein Proteins 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 102000003425 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 108010084455 Zeocin Proteins 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
• 108010091268 alpha-Macroglobulins Proteins 0.000 description 1
• 102000018162 alpha-Macroglobulins Human genes 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 1
• 108010052590 amastatin Proteins 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 230000003092 anti-cytokine Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002788 anti-peptide Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 239000012148 binding buffer Substances 0.000 description 1
• 230000003851 biochemical process Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000011722 cellular response to heat Effects 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 230000037012 chymotrypsin-like activity Effects 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 230000002281 colonystimulating effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000005056 compaction Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 108050004038 cystatin Proteins 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 239000005546 dideoxynucleotide Substances 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 101150052825 dnaK gene Proteins 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000000147 enterotoxin Substances 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000005252 hepatitis A Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 102000053548 human HSPB1 Human genes 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 230000037189 immune system physiology Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000002998 immunogenetic effect Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 238000009403 interspecific hybridization Methods 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000015689 metaplastic ossification Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 201000006894 monocytic leukemia Diseases 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 229940051875 mucins Drugs 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 208000025189 neoplasm of testis Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 239000003973 paint Substances 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000009589 pathological growth Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229940056360 penicillin g Drugs 0.000 description 1
• 229950000964 pepstatin Drugs 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• 108010004108 peptidylglutamylpeptide hydrolase Proteins 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000009894 physiological stress Effects 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920002704 polyhistidine Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000007026 protein scission Effects 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940080313 sodium starch Drugs 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 229960002385 streptomycin sulfate Drugs 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 238000009966 trimming Methods 0.000 description 1
• 230000001810 trypsinlike Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 230000037455 tumor specific immune response Effects 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 238000007473 univariate analysis Methods 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000012130 whole-cell lysate Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 210000001325 yolk sac Anatomy 0.000 description 1